

The RAF/MEK clamp avutemetinib (VS-6766) induces an immunogenic tumor microenvironment and potentiates the efficacy of anti-PD-1

Silvia Coma¹, Miriam Molina-Arcas², Julian Downward² & Jonathan A Pachter¹

¹Verastem Oncology, Needham, MA, USA; ²The Francis Crick Institute, London, UK



BACKGROUND

The RAS/RAF/MEK/ERK (MAPK) pathway is one of the most commonly mutated oncogenic pathways in human cancers (1). Although RAS, RAF and MEK have been validated as anticancer targets with approval of KRAS G12C, BRAF and MEK inhibitors, combination strategies with chemotherapy, targeted therapies and/or immune checkpoint inhibitors may be optimal for deep and durable response (2, 3). Indeed, the combinations of the KRAS G12C inhibitors (G12Ci) sotorasib or adagrasib with anti-PD-1 have been clinically evaluated in first-line KRAS G12C non-small cell lung cancer (NSCLC) (4, 5) with adagrasib + anti-PD-1 showing a manageable safety profile and encouraging clinical activity.

Avutemetinib (VS-6766) is a unique RAF/MEK clamp that potently inhibits MEK kinase activity and induces dominant negative RAF/MEK complexes, preventing phosphorylation of MEK by ARAF, BRAF and CRAF (Figure 1) (6-8). Preclinically, avutemetinib potentiates G12Ci efficacy in KRAS G12C NSCLC models *in vivo* (Figure 2) (8) and two clinical studies of avutemetinib in combination with sotorasib (NCT05074810) or adagrasib (NCT05375994) for patients with KRAS G12C NSCLC are ongoing. Here, we tested the immune modulatory effects of avutemetinib on tumor cells and tumor-infiltrating immune cells and assessed anti-tumor efficacy in mice treated with avutemetinib ± G12Ci in combination with an anti-PD-1 antibody.




Figure 1. (A) Western blot analyses in HeLa cells treated with 1 μM avutemetinib (Avuto) or 1 μM trametinib (Tram) for 3 hours (8). **(B)** Schematic showing that avutemetinib is a unique RAF/MEK clamp that induces inactive complexes of MEK with ARAF, BRAF and CRAF. **(C)** Addition of avutemetinib to G12Ci might improve MAPK pathway blockade and anti-tumor efficacy through vertical inhibition of RAS, RAF and MEK.




Figure 2. (A) Changes in tumor volume in H2122 KRAS G12C NSCLC tumor-bearing mice treated with avutemetinib (0.3 mg/kg PO QD) ± sotorasib (30 mg/kg PO QD) (8). Trametinib was tested at 0.3 mg/kg PO QD. N=10 mice/group. SD: stable disease; PR: partial response. **(B)** Changes in tumor volume in KRAS(+G12C);p53null NSCLC GEMM mice treated with avutemetinib (0.1 mg/kg PO QD) ± sotorasib (100 mg/kg PO QD) (8). Trametinib was tested at 0.1 mg/kg PO QD. N=5-15 mice/group. CR: Complete response.

REFERENCES

- Shubert, Nat Rev Cancer 2027
- Cohen, Nat Rev Drug Discov 2021
- Hofmann., Cancer Discov 2022
- Li, Journal of Thoracic Oncology 2022
- Janne, ESMO Immuno-Oncology Congress 2022
- Ishii, Cancer Res, 2013
- Lito, Cancer Cell, 2014
- Coma, AACR meeting 2022

RESULTS

Avutemetinib upregulates antigen presentation machinery (MHC-I) in KRAS and BRAF mutant cancer models *in vitro* and *in vivo*




Figure 3. (A) A panel of KRAS and BRAF mutant cancer cell lines were treated with avutemetinib for 48h. Avutemetinib increased the expression of MHC-I complex genes including B2M, HLA-A and TAP-I. **(B)** CT26 KRAS mutant CRC tumor-bearing mice were treated with avutemetinib or trametinib at 0.3 mg/kg QD for 9 days. Avutemetinib upregulated B2M and TAP-I in the CT26 model. p value calculated using t test: ** = p<0.01; *** = p<0.001

Avutemetinib induces an immunogenic tumor microenvironment in the CT26 KRAS mutant syngeneic colorectal cancer model




Figure 4. CT26 KRAS mutant CRC tumor-bearing mice were treated with avutemetinib or trametinib at 0.3 mg/kg QD for 9 days. (A) Avutemetinib upregulated the expression of markers of T cells, interferon response, and NK cell activation. **(B)** Avutemetinib increased MHC-II expression by tumor cells, increased the numbers of CD8T cells and M1 macrophages, and decreased the number of monocytic and granulocytic MDSCs. p value calculated using t test: * = p<0.1; ** = p<0.01; *** = p<0.001; **** = p<0.0001

In the CT26 KRAS mutant syngeneic colorectal cancer model, combination of avutemetinib with anti-PD-1 results in increased antitumor efficacy and prolonged survival relative to single agents




Figure 5. CT26 KRAS mutant CRC tumor-bearing mice were treated with avutemetinib (0.5 mg/kg PO QD x28 days), anti-PD-1 antibody (3 mg/kg IP BIW x4 doses), avutemetinib + anti-PD-1 or vehicle. Tumor volume changes (A) and Kaplan-Meier survival curve (B) are shown.

Combination of avutemetinib + anti-PD-1 induces durable immune memory in the CT26 KRAS mutant syngeneic colorectal cancer model





Figure 6. CT26 KRAS mutant CRC tumor-bearing mice that were tumor-free after previous treatment with the combination of avutemetinib + anti-PD-1 were subsequent re-challenged with CT26 cells with no further treatment. Naive mice were used as positive control. Tumor volume changes (A) and percentage of memory CD4+ and CD8+ T cells in spleen (B) are shown.

Avutemetinib + adagrasib (KRAS G12C inhibitor) induces an immunogenic tumor microenvironment and improves survival in the KPAR^{G12C} orthotopic lung cancer model



CONCLUSIONS

- The RAF/MEK clamp avutemetinib (VS-6766) induced an immunogenic tumor microenvironment including upregulation of MHC-I and MHC-II antigen presentation machinery, and upregulation of markers of T cell and NK cell activation and interferon response. Furthermore, avutemetinib significantly increased the numbers of CD8 T cells and M1 macrophages with a concomitant decrease in monocytic and granulocytic MDSCs.
- Combination of avutemetinib with anti-PD-1 increased antitumor efficacy and prolonged survival relative to either agent alone in the CT26 KRAS mutant colorectal cancer model. Furthermore, avutemetinib + anti-PD-1 treatment induced durable immune memory.
- Combination of avutemetinib with adagrasib (KRAS G12C inhibitor) improved the immunogenic tumor microenvironment relative to adagrasib alone. This included increased granzyme production and reduced Tregs along with increased survival in the KPAR^{G12C} orthotopic lung cancer model.
- Preclinical evaluation of the triplet avutemetinib + adagrasib + anti-PD-1 is currently ongoing.
- These results support clinical evaluation of avutemetinib with anti-PD-1 for treatment of patients with MAPK pathway-dependent tumors as part of a doublet (e.g. avutemetinib + anti-PD-1 in BRAF mutant melanoma) or triplet (e.g. avutemetinib + adagrasib + anti-PD-1 in front-line KRAS G12C NSCLC).